)
Edge12 Dec 2025
Running on Clouds: The Story of On
The story of how a Swiss runner's pursuit of a new running sensation became On, aiming to be the most premium global sportswear brand worldwide.
Crinetics Pharmaceuticals
Crinetics Pharmaceuticals (CRNX) investor relations material
Crinetics Pharmaceuticals 44th Annual J.P. Morgan Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.44th Annual J.P. Morgan Healthcare Conference summary13 Jan, 2026
Business and Commercial Highlights
Achieved approval and successful launch of Palsinify (paltusotine) for acromegaly, with over 200 patients enrolled, strong prescriber adoption, and over $5 million in preliminary Q4 2025 net product revenue.
Built a fully integrated pharmaceutical company with robust infrastructure, commercial operations, and R&D, supported by approximately $1.4 billion in cash and investments as of January 2026, providing runway through 2030.
Strategic partnerships and spinouts include licensing paltusotine in Japan and collaborations in animal health, radiopharmaceuticals, and technology out-licensing.
Extensive patient support services and Quick Start program facilitate access and adherence, with payer acceptance and most prior authorizations granted for 12 months.
Positive patient testimonials highlight meaningful impact of PALSONIFY, improving quality of life for those with acromegaly.
Pipeline and Clinical Development
Advanced late-stage pipeline includes paltusotine for acromegaly and carcinoid syndrome, atumelnant for adult and pediatric CAH and ACTH-dependent Cushing's syndrome, and CRN09682 for neuroendocrine tumors.
Phase 3 trials underway for paltusotine in carcinoid syndrome and atumelnant in adult CAH, with pediatric CAH trial planned for 1H2026; Phase 1/2 underway for CRN09682.
Paltusotine showed positive Phase 2 data in carcinoid syndrome, reducing flushing and bowel movement frequency, and is being evaluated in a Phase 3 trial.
Atumelnant demonstrated robust efficacy and safety in Phase 2, with up to 80% reduction in A4 biomarker and no serious or severe treatment-related adverse events.
CRN09682, a novel small molecule targeting SST2, showed promising preclinical results and entered Phase 1/2 for neuroendocrine tumors.
Growth Strategy and Market Access
Focused on expanding prescriber base and patient activation, especially among untreated and undiagnosed acromegaly patients.
Real-world data and patient ambassador programs to drive awareness and adoption, with ongoing efforts to improve diagnosis rates and broaden market reach for Palsinify.
No plans to discount to commercial payers; gross to net driven by payer mix and 340B institution participation.
Achieved payer acceptance, with CVS Caremark adding Palsinify to formulary.
What is the strategy to engage undiagnosed acromegaly patients?
Mitigating Phase III CAH trial execution risks
9682: Prioritize non-NET SST2+ tumor indications
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Crinetics Pharmaceuticals earnings date
Q4 202526 Feb, 2026
Crinetics Pharmaceuticals
Next Crinetics Pharmaceuticals earnings date
Q4 202526 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Crinetics Pharmaceuticals Inc. is a clinical-stage pharmaceutical company that specializes in the development of novel therapeutics targeting peptide hormone receptors. Their focus is on the treatment of rare endocrine disorders and endocrine-related tumors. The company’s leading product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist. It is in advanced clinical trials for conditions such as acromegaly, carcinoid syndrome, and nonfunctional neuroendocrine tumors. Additionally, Crinetics Pharmaceuticals is developing other drug candidates for conditions like congenital hyperinsulinism and Cushing's disease. The company is headquartered in San Diego, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage